Ahn, E. R., Garrett-Mayer, E., Halabi, S., Mangat, P. K., Calfa, C. J., Alva, A. S., … Schilsky, R. L. (2020). Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Ahn, Eugene R., Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Carmen Julia Calfa, Ajjai Shivaram Alva, Vijay S. Suhag, et al. “Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Ahn ER, Garrett-Mayer E, Halabi S, Mangat PK, Calfa CJ, Alva AS, et al. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Ahn, Eugene R., et al. “Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Ahn ER, Garrett-Mayer E, Halabi S, Mangat PK, Calfa CJ, Alva AS, Suhag VS, Hamid O, Dotan E, Yang ES-H, Alese OB, Yost KJ, Marr AS, Palmer MC, Thompson FL, Rygiel AL, Anderson ST, Islam S, Schilsky RL. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2020.